Aptorum Group (Aptorum Group) Repurchase of Stock : $0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Repurchase of Stock?

Aptorum Group's Repurchase of Stock for the six months ended in Jun. 2023 was $0.00 Mil.

Aptorum Group's Repurchase of Stock for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

Aptorum Group Repurchase of Stock Historical Data

The historical data trend for Aptorum Group's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Repurchase of Stock Chart

Aptorum Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Repurchase of Stock

Get a 7-Day Free Trial

Aptorum Group Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Repurchase of Stock	Get a 7-Day Free Trial							-	-	-	-	-

Aptorum Group Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Aptorum Group Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptorum Group (Aptorum Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Repurchase of Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.aptorumgroup.com

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.